←
Diogo Martins Branco916 posts
Diogo Martins Branco avatar

Diogo Martins Branco

@DMBranco

#medonc MD 🇵🇹 & #pallonc MSc 🇬🇧 | @myESMO Scientific&Medical Advisor 🇨🇭 | #research #education #policy | Views are own 🎾

◷ Joined July 2017▧ 194 Photos and videos
Diogo Martins Branco avatar
Diogo Martins Branco@DMBranco·26 Aug 2024

📢#CancerTherapy claiming #TumourAgnostic potential❓ ✔ ORR≥20% in 2/3 of tumour types investigated (≥4) with ≥5 evaluable patients per tumour type 🔓@myESMO Tumour-Agnostic Classifier & Screener (ETAC-S) @Annals_Oncology @BenWestphalen @VivekSubbiah @GPentheroudakis et al

ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process @Annals_Oncology. 🔗ow.ly/rqmR50T6gHt

Post attachment
Guilherme Nader Marta avatar
⟳ Diogo Martins Branco retweeted
Guilherme Nader Marta@GuiNaderMarta·Oct 24

Important data presented at #ESMO2026 TROPION-Breast02 | 1L mTNBC with brain metastases • Median CNS PFS: 9.5 vs 2.6 months (HR 0.27) • Intracranial ORR: 62.5% vs 37.5% Dato-DXd showed great activity, regardless of prior CNS-directed therapy in TNBC @OncoAlert

Post attachmentPost attachment
OncoAlert avatar
⟳ Diogo Martins Branco retweeted
OncoAlert@OncoAlert·Oct 22

Precision oncology🎯 is evolving—but how do we distinguish a promising molecular target🧬 from one supported by evidence strong enough to guide treatment? sciencedirect.com/science/ar… The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology ESCAT v2 updates the ESMO framework for assessing molecular target actionability in precision oncology. ➡️ The revised classification refines evidence certainty within actionable tiers, introduces formal tumour-agnostic eligibility criteria through ETAC-S, and distinguishes non-predictive biomarkers from ineffective biomarker–therapy matches. ➡️ A complementary four-level resistance scale classifies evidence from clinically validated resistance to preclinical findings. ✅️ Together, these updates support more consistent interpretation of sensitivity and resistance biomarkers, helping guide therapeutic decisions and research priorities. @AyaHelali, @niamhjcoleman, @ekocakavuk, @clare__turnbull, @FerMosele, @CDebyaniPhD, @rdienstmann, @herbloong, @DMBranco, @quimmateo, @BenWestphalen

Post attachment
ESMO - Eur. Oncology avatar
⟳ Diogo Martins Branco retweeted
ESMO - Eur. Oncology@myESMO·Sep 30

ESMO Frameworks help provide the standards, guidance and shared language needed to support informed decision-making across #CancerCare. Discover why frameworks matter and the value they bring to the #OncologyCommunity. 📌esmo.org/frameworks-and-tool… ​ @FAndreMD

0:33

As oncology continues to evolve, innovation alone is not enough. Evidence-based standards, classifications and frameworks are essential to support consistent implementation in #ClinicalPractice across health systems. ​🔗ow.ly/RnwY50ZOlAf ​ @FAndreMD

Post attachment
ESMO - Eur. Oncology avatar
⟳ Diogo Martins Branco retweeted
ESMO - Eur. Oncology@myESMO·Sep 10

ESMO's new Clinical Trials Funding initiative supports independent academic pragmatic clinical trials to improve #CancerCare and patient outcomes. Open to academic institutions, hospitals, research groups. Application deadline: 1 November 2026 ow.ly/482Q50ZLX3p

Post attachment
ESMO - Eur. Oncology avatar
⟳ Diogo Martins Branco retweeted
ESMO - Eur. Oncology@myESMO·Aug 24

👉 By E de Azambuja and N Harbeck, the ESMO Metastatic Breast Cancer Living Guideline provides immediate access to the June 2026 CPG recommendations, with notable systemic treatment updates in several subtypes, in an interactive, mobile-friendly format 🔗 ow.ly/jN5E50ZEoqy

Post attachment
ESMO - Eur. Oncology avatar
⟳ Diogo Martins Branco retweeted
ESMO - Eur. Oncology@myESMO·Apr 21

A new ESMO consensus driven document standardises definitions, formats and minimum data for enumerating and reporting prior lines of therapy across solid tumours, supporting consistent trial design and comparable outcomes. #ESMODailyReporter 🔗 ow.ly/vFkl50YNkkb

Post attachment
Juliana Beal, MD avatar
⟳ Diogo Martins Branco retweeted
Juliana Beal, MD@JulianaRBeal·Apr 15

@myESMO webinar on tumor agnostic therapies: amazing effort by a diverse group of oncologists to develop (and update) frameworks which will aid the decision on when to deliver histology independent biomarker-drug combinations

Post attachment
Mirrors of Medicine avatar
⟳ Diogo Martins Branco retweeted
Mirrors of Medicine@mirrorsmed·Jan 5

Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01) aacrjournals.org/clincancerr… This study uses AURORA multi-omics 🧬data to characterize gene fusions in metastatic #BreastCancer and their clinical relevance. Analysis of RNA sequencing from primary and metastatic tumors revealed a higher gene fusion burden in metastases, with acquired fusions linked to genomic instability and subtype-specific copy-number gains, particularly involving genes within the same topologically associating domain. These fusions were associated with poorer prognosis in ER-positive/HER2-negative tumors, with ESR1 fusions marking especially aggressive disease, highlighting gene fusions as potential drivers of progression and therapeutic targets. Chiara Biagioni @Fimereli_Danai @AlexIrrthum @AngelZotano @Carmela_surgery @DMBranco @ElisaAgostinett @ZoppoliGabriele @AnaVivancosVHIO @MOliveira_MD @curijoey @c_sotiriou @aftimosp Matteo Benelli @UNI_FIRENZE

Post attachment